https://orcid.org/0000-0002-9461-7575
References
- Re D, Fuchs M, Schober T, et al. CNS involvement in Hodgkin’s lymphoma. J Clin Oncol. 2007;25(21):3182.
- Cheah CY, Bröckelmann PJ, Chihara D, et al. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: an international multicenter collaboration. Am J Hematol. 2016;91(9):894–899.
- Sapozink MD, Kaplan HS. Intracranial Hodgkin’s disease. A report of 12 cases and review of the literature. Cancer. 1983;52(7):1301–1307.
- Gerstner ER, Abrey LE, Schiff D, et al. CNS Hodgkin lymphoma. Blood. 2008;112(5):1658–1661.
- Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended Follow-Up of the multicohort Single-Arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439.
- Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
- Apostolidis J, Sayyed A, Darweesh M, et al. Current clinical applications and future perspectives of immune checkpoint inhibitors in Non-Hodgkin lymphoma. J Immunol Res. 2020;2020:9350272.
- Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277.
- Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–2697.
- Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337–341.
- Berghoff AS, Venur VA, Preusser M, et al. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book. 2016;35:e116–e122.
- Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073.
- Portnow J, Wang D, Blanchard MS, et al. Systemic anti-PD-1 immunotherapy results in PD-1 blockade on T cells in the cerebrospinal fluid. JAMA Oncol. 2020;6(12):1947–1951.
- Fu H, Shi S, Chen L, et al. Primary central nervous system Hodgkin’s lymphoma: a case report. J Int Med Res. 2021;49(4):300060521999533.
- Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–3979.